A retrospective study found a link between erythropoiesis-stimulating agents and leukemic transformation in primary myelofibrosis patients. The research confirmed clinical and laboratory variables associated with leukemia development, including specific treatments that increased the risk of leukemic transformation.
A phase II trial of Cybor-D, a combination therapy including cyclophosphamide, bortezomib, and dexamethasone, showed an improved response rate compared to traditional lenalidomide-dexamethasone therapy. The treatment resulted in a rapid initial decline and percentage reduction in M protein levels.
A peptide vaccine for leukemia improved event-free survival by 8.7 months compared to non-responders, with 36% of responders experiencing complete cytogenetic remission. The vaccine targets cancer cells and induces a specific immune response in patients with HLA-A2
Researchers announced new data showing Gleevec improves outcomes for children with Ph+ ALL, reversing the poor prognosis, and prevents disease progression in adults with CML. Continuous treatment with Gleevec has shown a declining rate of relapse over time, with no patients progressing to advanced phase in CML.
A new study reveals microRNAs can directly control a protein's function, preventing immature blood cells from maturing and contributing to the development of blast-crisis CML. Altering microRNA levels may represent a potential therapeutic strategy for CML patients who don't respond to targeted agents.
Two drugs, dasatinib and nilotinib, are showing promising results as frontline therapy for newly diagnosed CML patients with high complete cytogenetic response rates of approximately 90% at 6 months. The treatments target a greater variety of genetic variations than imatinib, which has increased the 5-year survival rate for CML patient...
Abnormal stem cells with deletions of chromosome 7 or duplications of chromosome 8 have been found in some CML patients, suggesting new targets for therapy. The discovery opens a new window into understanding the roots of chronic myeloid leukemia.
A Phase III clinical trial shows that patients with relapsed CLL who achieve complete response with oblimersen combination therapy live significantly longer than those treated with chemotherapy alone. The median survival time for oblimersen-treated patients is estimated to exceed 49 months, whereas it was 35 months for those on F/C alone.
A clinical trial by Mayo Clinic found a lower dose of steroids to be as effective as the standard high-dose treatment in improving overall survival rates for multiple myeloma patients. The new regimen, lenalidomide plus low-dose dexamethasone, showed significantly better results with less toxicity.
Results from two Phase I trials demonstrate clinical activity of ZOLINZA (vorinostat) combined with bortezomib in patients with relapsed and/or refractory multiple myeloma. The combination treatment showed partial or minimal responses in 48% of evaluable patients, suggesting potential for further evaluation in randomized clinical trials.
Findings from two large clinical trials demonstrate significant improvement in patients with multiple myeloma who received Revlimid, an oral cancer drug, compared to those receiving a placebo. The study showed improved median survival and response rates, offering new hope for patients with this challenging disease.
A new study by Brandeis University researchers finds that many pediatric oncologists lack the necessary training to build bridges with families of critically ill children through religion and spirituality. The study suggests that providing this type of training could improve patient outcomes.
A study of 454 patients with chronic-phase CML taking imatinib for over six years found a high estimated six-year survival rate of 76 percent and strong correlation between overall survival rates and cytogenetic response. The incidence of serious side effects was low, with no long-term new toxicities observed.
Two studies found a significant increase in five- and ten-year survival rates for MM patients over the past decade, with younger patients showing the most dramatic improvement. Novel therapies have been credited with this trend, particularly among younger patients.
Scientists at MIT have identified a critical blood protein called HRI that plays a pivotal role in the body's iron recycling process. This discovery holds promise for developing new treatments for conditions like beta-thalassemia and erythropoietic protoporphyria.
A cohort study of 8,755 employees found that long-haul flights significantly increased the risk of developing deep vein thrombosis. The researchers estimate that airline passengers are at least twice as likely to develop DVT during a long-haul flight compared to non-air travelers.
A long-term study found that stem cell transplant patients experience decreased sexual function and activity, particularly in females. While males recover partially over time, females remain compromised. The study suggests systemic therapies and chronic graft-versus-host disease contribute to sexual dysfunction.
Researchers at UCLA identified a distinct pattern of gene expression in immune cells from chronically lonely individuals. This finding suggests that social isolation affects the activity of genes driving inflammation and may provide a molecular framework for understanding its link to heart disease, viral infections, and cancer.
Emory researchers identify Ribosomal S6 kinase 2 (RSK2) as a critical downstream signaling protein effector of FGFR3 in myeloma cells. RSK2 plays a key role in regulating cell cycle and survival, and targeting it with drugs may be effective in treating multiple myeloma.
Researchers developed a genetic dosing model to predict optimal warfarin dose for patients undergoing orthopedic surgery. The model combines genotype information with clinical factors to estimate therapeutic dosage.
Researchers identified an unusually high rate of severe allergic reactions to cetuximab among patients living in the middle South, with a 22% rate compared to 2% nationwide. The strongest predictor of a reaction was a history of other hypersensitivities.
Researchers found that high-dose chemotherapy and blood stem cell transplantation can result in long-term survival for patients with primary systemic light chain (AL) Amyloidosis. The median survival for all 80 patients was 57 months, with 18 still alive 10+ years after treatment.
Researchers at Virginia Commonwealth University identified two key proteins, KLF2 and EKLF, that regulate overlapping groups of genes during red blood cell development. The study may lead to future gene therapies for sickle cell anemia and beta-thalassemia.
A study led by Duke University researchers found that a white blood cell booster can significantly reduce the risk of chemotherapy-related complications characterized by fever and low white blood cell levels. The study, published in the Journal of Clinical Oncology, involved over 3,000 patients and showed that patients taking the drug ...
A study estimates nearly one-third of hospitalized US patients are vulnerable to VTE, which can lead to dire complications. Researchers stress the need for reinforcing national guidelines and monitoring compliance with hospital protocols for VTE prevention, as well as educating outpatients on preventive measures.
Researchers from Boston University Medical Center successfully treat patients with immunoglobulin-light chain amyloidosis who did not respond to initial treatment. A tandem approach of high-dose chemotherapy and blood stem cell transplantation shows improved overall survival and quality of life for these patients.
Researchers at Children's Hospital Boston have found a new way to increase stem cells in blood, suggesting a possible treatment to help patients recover their immune function more quickly. The discovery uses a small-molecule drug that enhances the blood-forming system.
Researchers at UCLA's Jonsson Cancer Center have discovered a novel anti-inflammatory cell signaling pathway that may serve as a vital Yin-Yang mechanism to maintain the delicate balance of immune response. This discovery may lead to new ways to fight cancer and inflammatory diseases.
A recent study published in The Lancet found that mismatched cord blood transplants performed as well as matched bone marrow transplants in terms of leukemia-free survival rates. Additionally, patients receiving matched cord blood had a 20% higher survival rate than those with matched bone marrow.
The Revlimid data presented at ASCO demonstrates a greater one-year survival advantage for patients receiving low dose dexamethasone compared to those receiving the standard high dose of the steroid. In all age ranges, patients benefit from Revlimid with the low dose dexamethasone, showing improved survival rates.
Researchers have confirmed that arsenic trioxide significantly improves patient survival in newly diagnosed acute promyelocytic leukemia (APL) patients. Nearly 600 patients participated in a six-year phase III study, showing improved disease-free rates and longer survival compared to standard chemotherapy alone.
Researchers discovered patterns of cellular activity that confer poorer prognoses in younger women with breast cancer, highlighting the need for age-appropriate targeted therapies. The study aims to identify effective treatments targeting these tumor cell activities in premenopausal women.
A new study published by Duke University Comprehensive Cancer Center found that patients with chronic illnesses like diabetes or heart disease are no more likely to receive an early cancer diagnosis due to frequent healthcare interactions. Screening is still crucial regardless of medical management.
The OHSU Cancer Institute study found that sipuleucel-T vaccine slowed the rate of rise of serum PSA in exploratory analyses, but did not significantly delay cancer progression. The treatment also showed a favorable safety profile with common side effects like fatigue and chills.
Researchers have identified C-reactive protein (CRP) as a strong indicator of survival for men with advanced prostate cancer. The study found that higher levels of CRP are associated with shorter survival and lower response to chemotherapy.
Researchers found that a gene deficiency in CalDAG-GEFI may explain the loss of platelet function leading to recurrent bleeding in patients with leukocyte adhesion deficiency III. Additionally, IL-33 and ST2 signaling was identified as a critical mechanism for protecting the heart from stress, suggesting potential new therapeutic targets.
Researchers found that patients who received Gleevec after surgery were significantly less likely to have cancer recurrence compared to those who didn't receive it. The study showed a 97% survival rate for patients on Gleevec, with only mild side effects reported.
Researchers at the University of Utah Health have made a significant breakthrough in understanding the origins of synovial sarcoma, a deadly cancer that affects young adults. By engineering mice to develop this cancer, scientists discovered that it originates from muscle cell precursors known as myoblasts.
A new study led by the University of Georgia finds that older breast cancer survivors experience persistent physical and emotional challenges, with reduced quality of life. The research highlights the need for targeted interventions to improve well-being among this population.
A study from UNC School of Medicine suggests that improving healthcare access is key to reducing disparities in prostate cancer among black men. The lack of regular healthcare and trust in physicians hindered their ability to receive preventative care, leading to higher death rates.
Researchers found a close correlation between vancomycin exposure and severe thrombocytopenia with serious bleeding. The antibiotic was discontinued in most cases, resulting in normal platelet counts.
Researchers discovered that cancer cells forming blood vessels exhibit a distinct distribution of cellular copper, which may help explain how copper-reducing cancer therapy works. This finding has implications for understanding the regulation of metal ion content in metal-binding proteins and could lead to new cancer therapies.
Two promising blood cancer researchers, Giovanni Roti and Marta Crespo, will each receive $75,000 to fund their research in the US. The EHA-ASH International Fellowship Award aims to build stronger ties between European and North American scientific communities.
Researchers from UNC and Dana Farber Cancer Institute found that industry-funded breast cancer trials are more likely to have positive outcomes compared to non-pharmaceutical funded studies. The study also revealed significant differences in clinical trial design and outcome between industry-supported and non-industry studies.
International team develops standardized guidelines for assessing lymphoma treatment response, incorporating new imaging technologies. The revised guidelines aim to improve therapies and facilitate the development of new treatments.
Children with sickle cell disease who experienced major complications such as pain and lung disease early in life are not at greater risk for stroke or death during later childhood, according to new research. Children hospitalized for chest problems early on are more likely to see those problems recur up to adulthood.
Scientists identified an approach to boost the activity of dasatinib, a potent anti-cancer agent, by combining it with PD184352. This combination resulted in increased apoptosis in leukemia cells, particularly those resistant to imatinib mesylate.
Researchers at the University of Minnesota successfully used adult stem cells to replace the immune system and bone marrow of mice, offering a promising new therapy for people in the future. The study replicated previous findings and demonstrated that multipotent adult progenitor cells (MAPCs) can give rise to blood cells.
Teens with cancer face poor survival rates due to limited clinical trial participation, lack of awareness about their risk, and delayed diagnoses. The 15-29 age group has seen no improvement in survival rates over the past 25 years.
Researchers at City of Hope and St. Jude Children's Research Hospital developed a modified neural stem cell therapy that activates chemotherapeutic drugs primarily at tumor sites, sparing normal tissue. The approach showed promise in treating solid tumors, including neuroblastoma, with improved survival rates.
Avastin, an anti-angiogenic therapeutic, improves lung cancer patient survival by 20% and reduces side effects compared to conventional chemotherapy. The drug targets tumor blood vessels, enabling chemotherapy drugs to diffuse into the tumor more effectively.
AkaRx Inc. presents Phase I clinical data of AKR-501, a TPO receptor agonist that mimics the effect of thrombopoietin to stimulate platelet production, with a 50% increase in platelet count in healthy volunteers. The results suggest potential for safe and effective treatment of thrombocytopenia in various diseases.
A clinical trial combining bortezomib with Doxil has shown promising results in treating relapsed or refractory multiple myeloma, a type of bone marrow cancer. The combination treatment demonstrated a better response rate compared to standard therapy alone, with a median time to progression of 9.3 months.
Researchers at Mayo Clinic Cancer Center have led efforts to test new therapies in multiple myeloma, improving effectiveness and reducing toxicity. Studies show high response rates with lenalidomide and bortezomib, and a synergistic effect when targeting both tumor cells and microenvironment.
A Phase I clinical trial found that combining bortezomib and lenalidomide showed durable responses in patients with resistant multiple myeloma. The combination therapy was well-tolerated, with only mild side effects.
Researchers with Bank On A Cure identified genetic pathways associated with venous thromboembolisms in patients treated with thalidomide for multiple myeloma. These findings may lead to screenings and tailored interventions to prevent blood clots, as well as the development of new treatments.
Researchers aim to reduce complications from bone marrow transplants by replenishing a natural host defense factor depleted during chemotherapy. A new multicenter study will test rBPI21, a manufactured form of BPI, in HSCT patients.
The study presents positive interim results of using ALDESORT to isolate cord blood stem cells, showing improved overall survival at 90.9% compared to a historical control group. The infusion of cells enriched with ALDESORT appears to improve the speed and efficacy of cord blood transplantations.
Researchers at Mayo Clinic Cancer Center found that tipifarnib can stall or reverse disease progression for patients with relapsed aggressive non-Hodgkin lymphoma. The study showed a partial response in 18% of patients and stable disease in 21%, while also improving quality of life.
The study found that AVN944 significantly inhibited the IMPDH enzyme and induced biomarkers associated with cancer cell death. The gene HspA1A marker was elevated even at low doses of the drug, indicating potential for tumor cell apoptosis.